#ASCO22
✳️Happy to say there is great progress for patients with CRC‼️
@OncoAlert @ASCO @manjuggm @CrcChange‼️
Here is summary of some key studies 👇
1️⃣ Immune checkpoint inhibitor monothetapy with dostarlimab for MMR-D is certainly practice changing❗️

✳️Although long term outcomes are needed, no need to reinvent the wheel‼️

✳️ Once a deep response achieved in MMR-D CRC it is very durable even in metastatic setting ‼️
2️⃣ #ctDNA study (DYNAMIC) was my second favorite study ❗️

✳️ We are certainly in the right pathway to use #ctDNA however we have to be careful for false negative results in high risk population: T4 disease ‼️

✳️We need more trials to get more data ❗️Enroll COBRA/CIRCULATE
3️⃣ NICHE trial is quite provocative and highly exciting for MSI-H and perhaps somewhat promising for MSS colon❗️

✳️A downside of the study to identify right population to treat in neoadjuvant setting ! Radiological staging has not been well established for colon cancer ‼️
4️⃣ For example, do we really need IO for patient with N(-) and/or T3 know IRAEs❓Where ctDNA settles in?

✳️if WW is considered as evolving approach, then cCR for colon cancer is not well established unlike rectal‼️

✳️ Also we need to keep our CR surgeons in business ☺️
5️⃣ 29% Major response (not all cCR) in MSS is nice but we have to acknowledge even metastatic setting chemotherapy has higher response rate ‼️

✳️ Nonetheless seeing some response with IO alone for pts with MSS is exciting and warrants more correlative ❗️
6️⃣NIVACOR Trial investigated the chemoimmunotherapy and maintenance bev+IO combination for pts with nCRC❗️

✳️ Single arm study and inclusion of pts with MSI-H CrC makes it hard to evaluate the additive role of IO ‼️

✳️It is time to separate trials for MSI-H/MSS (actually due)❗️
7️⃣More and more studies investigating the nonoperative approach for rectal cancer ❗️

✳️New XRT modalities and dosing seem to be on improving organ preservation‼️

✳️Glad there is consensus in enthusiasm on this pathway ❗️
8️⃣Clonal evolution of colorectal cancer allows to rechallenge EGFR responsive therapies as long as downstream mutations (RAS/RAF) does not occur‼️

✳️EGFR rechallenge trials are quite relevant and exciting to see the interest is continuing to evolve!
9️⃣ The PARADIGM trial remonstrated what FIRE-3 trial ! No practice changing rather confirming ‼️

✳️Left sided CRC responds better EGFR blockadeand can be considered as first biologic agent in combination with chemotherapy
1️⃣0️⃣ The Optical trial is important❗️

✳️This study looked into perioperative chemotherapy DID not improve DFS‼️

✳️I get worried about correct clinical staging of colon cancer in locally advance setting unlike rectal cancer. Overtreatment vs Undertreatment (with CIRCULATE-US)
1️⃣1️⃣The IMPROVE trial offers an approach with intermittent use EGFR blockade to avoid toxicity and decrease resistance‼️

✳️I think this is relevant for toxicity (increase compliance) but not sure this addresses resistance perhaps changes the course of clonal evolution ❗️
1️⃣2️⃣ Conflicting results with Bevacizumab versus Anti-EGFR containing triplet regimens‼️

✳️We know bevacizumab works better with triplet mostly due to toxicity of anti-EGFR with triplet may become overwhelming (rash/diarrhea:fatigue)!
1️⃣3️⃣One thing I believe causing confusion clinical trial inclusion criteria and inclusion of pts with right sided colon cancer ‼️

✳️Nonetheless, as of now, bevacizumab seems be a better companion for triplet chemotherapy ‼️

✳️We need more studies with clearer designs❗️
1️⃣4️⃣ Perhaps there are so many other exciting studies could not include here, But the progress in #ASCO22 for pts with CRC is very encouraging and I am happy to see that for our patients‼️

✳️That being said there is significant unmet need for precision medicine and immunotherapy
1️⃣5️⃣An add on (recognized that I missed that important one)‼️

✳️Removing primary for pts with unresectable metastatic disease do no benefit and should be avoided as this approach delays initiation of systemic therapy ‼️

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Ibrahim Halil SAHIN, MD

Ibrahim Halil SAHIN, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @IbrahimSahinMD1

Jun 5
#ASCO22

✳️The standard of care for MMR-D rectal cancer is changing/changed❗️
✳️We should do all we can to avoid surgery for patients with MMR-D rectal cancer ❗️
✳️Although data is early and it is highly promising enough to move forward ‼️@asco @OncoAlert @MoffittNews
👇
✳️Perhaps important to note that 100% clinical response is not complete pathological response ‼️

✳️However this is higher than we achieved with OPRA in MSS rectal cancer ‼️

✳️Also, all patients had BRAF WT which is expected (Lynch cause more MMR-D rectal than sporadic event)
✳️As next step we should consider adding anti-CTLA4 blockade after seeing long term outcomes, if needed ‼️
✳️Very exciting time for patients with MMR-D CRC and great to see this change in this field and happy for our patients ‼️
Read 4 tweets
Jun 4
#ASCO22
✳️DYNAMIC trial results are highly exciting and glad to see field is moving forward !

✳️Very encouraging findings that we are in right pathway to use #ctDNA for adjuvant tx‼️

However there are important points that we need to address 👇@ASCO @OncoAlert @MoffittNews ImageImageImageImage
✳️Firstly, I am categorically against putting T4 and T3 disease into same pocket (stage II is highly heterogeneous)❗️

✳️Risk of peritoneal recurrence for T4 and T3 is not same and not even close ‼️

✳️Peritoneal microscopic disease doesn’t shed CtDNA as much as liver MRD‼️
✳️Moreover, control group was a bit vague in this study, conventional risk factors are used for ad therapy which can offer you different approaches ‼️

✳️Currently there is not consensus for high risk stage II in NCCN and options include observation vs FP alone or doublet ‼️
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(